European Leukemia Trial Registry
Trial: AML AZA

More Details
Title 5-azacytidine added to standard primary therapy in elderly patients
Scientific Title A randomized, multi-center phase II trial to assess the efficacy of 5-azacytidine added to standard primary therapy in elderly patients with newly diagnosed AML
Short Title AML AZA
Trialgroup SAL
Type of Trial multicentric, randomized, prospective, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age > 60 years
Status Closed
Start of Recruitment 01.05.2009
Leader Müller-Tidow, Prof. Dr. med., Carsten
Contactperson

Study Physician
Koschmieder, Anja
Tel: +49 (0)251 83-44801 oder 58375

Study Physician
Krug, PD Dr. med., Utz
Tel: +49 (0)214 13-2671
Fax: +49 (0)214 13-2198
Email: utz.krug@klinikum-lev.de

Centre of Trial Universitätsklinikum Münster
Shortprotocol Shortprotocol
Diagnostics

Central diagnostics
Hämatologisches Labor, Universitätsklinikum Dresden
Molekulargenetik-Labor der Med.Klinik II, Universitätsklinikum Frankfurt
Labor für Spezielle Hämatologie und Immunphänotypisierung, Universitätsklinikum Münster

Remark www.sal-aml.org
created 12.12.2008 5 Roswitha Kotthoff
changed 05.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org